AAIC 2026 in London showed a blood test helped primary-care doctors diagnose Alzheimer's with specialist-level accuracy. Patients with memory concerns can start with their regular doctor instead of waiting for a specialist. The test is C2N Diagnostics' PrecivityAD2. It measures amyloid-beta ratios and phosphorylated tau, including %p-tau217, to aid Alzheimer's diagnosis.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the Swedish study test?
- How much did accuracy improve?
- Will this change your care plan?
- Who can get the FDA-cleared test?
- Can p-tau217 predict future risk?
What did the Swedish study test?
Lund neurologist Sebastian Palmqvist led a prospective real-world study in Sweden. It enrolled 1,310 patients with mild impairment or dementia and 165 physicians.
The study evaluated PrecivityAD2 as an aid alongside clinical exams. Doctors made a diagnosis first, then saw the blood result and reassessed.
How much did accuracy improve?
Among 383 primary-care patients, physician accuracy rose from 65% before results to 93% after. Clinical Lab Products reported that gain in its coverage of the meeting meeting report.
That 93% matched dementia specialists at about 90-94%. For patients, it means fewer missed cases and fewer wrong labels in a regular clinic visit.
Will this change your care plan?
After reviewing results, doctors changed the diagnosis in about one-third of patients. They also changed planned care or exams in more than half.
The greatest value was ruling out Alzheimer's in primary care. A negative result can spare spinal taps, scans, and long specialist waits, while a positive result supports a timely referral.
- track symptoms, onset dates, and daily impacts
- bring medications, sleep issues, and other conditions
- ask whether a blood result changes diagnosis, tests, or referral
Who can get the FDA-cleared test?
C2N Diagnostics announced FDA clearance on Aug. 20, 2026 for symptomatic adults age 40 and older company announcement.
It is an adjunct to clinical workup, not screening or a stand-alone diagnosis. Healthy adults without symptoms do not qualify. Your doctor still must combine history, exam, and thinking tests with the blood result.
Can p-tau217 predict future risk?
A separate AAIC 2026 pooled analysis followed about 2,700 cognitively healthy adults. The Alzheimer's Association reported that very high plasma p-tau217 carried about 38% risk of impairment at 5 years and 78% at 10 years Association release.
That analysis by Rachel Buckley and colleagues was simultaneously published in JAMA. It adds risk information beyond PET amyloid and genetics for trial selection and monitoring. For now, ask your primary-care doctor about evaluation if memory or thinking problems interfere with daily life.
You Might Also Like
- AAIC 2026 Primary Care Alzheimer’s Blood Test Findings: What Changed and What Comes Next for Primary Care Patients
- Why the AAIC 2026 Soccer Study Does Not Prove Dementia: Questions Adult Children Can Ask About the Research
- Why the AAIC 2026 Soccer Study Does Not Prove Dementia: How Adult Children Can Avoid Overreading the Headline
